An observational study in Prostate Cancer, sponsored by East and North Hertfordshire NHS Trust. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by East and North Hertfordshire NHS Trust · Observational
This small study will investigate the feasibility of using multi-parametric MRI to introduce and support adaptive radiotherapy treatments for high-risk prostate cancer.
Mount Vernon Cancer Centre at East and North Hertfordshire NHS Trust offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder or cervix changes in bladder and uterus size and position can be predicted allowing the prospective creation of three radiotherapy treatment plans, each day the best fitting plan, i.e. the one that closely covers the tumour whilst giving minimal dose to normal tissues, is selected and used for treatment, this is known as plan-of-the-day adaptive radiotherapy.
Small changes in shape and position of the prostate occur but are generally the result of rectal changes which cannot be predicted, consequently adaptive radiotherapy based on physical change is not possible for prostate cancer treatments. However, recent literature suggests that magnetic resonance imaging (MRI) can detect changes within the prostate in response to radiotherapy, some studies have seen changes as early as the second week of radiotherapy treatment. A feasibility study to investigate if these changes can support radiotherapy treatment plan adaption for prostate cancer treatments is proposed, whether the plan can be adapted to give a higher treatment dose to any areas of the prostate that show poor response to radiotherapy without increasing bowel and bladder dose is of particular interest. The treatment for patients who participate in the study would not be changed but the results may help to personalise and improve the treatment of future patients.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 5 is below the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →East and North Hertfordshire NHS Trust is the lead sponsor of 36 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
15 male patients scheduled to receive androgen deprivation therapy and external beam radiotherapy for high-risk prostate cancer at Mount Vernon Cancer Centre.
New diagnosis of high-risk prostate cancer: any of:
Exclusion Criteria:
Reproducability of DW-MRI
Apparent diffusion coefficient (ADC)
Time frame: 7 months
Reproducibility of DCE-MRI
Using volume transfer constant
Time frame: 7 months
Reproducibility of DCE-MRI
Using leakage space as a percentage of unit volume
Time frame: 7 months
Reproducibility of DCE-MRI
Using rate constant
Time frame: 7 months
MP-MRI Response Correlation
Developing methods to identify and delineate areas of tumour according to their response to radiotherapy treatment by correlating MP-MRI kinetic parameters with anatomical T2 MRI images
Time frame: 7 months
Assessment of adapted dosimetry
Amount of acceptable radiotherapeutic dose
Time frame: After week 3 of radiotherapy
Assessment of cell kill
Proportion of cells killed at given dose following androgen deprivation therapy
Time frame: 3 months
Tumour response prediction
Assess which proportion of tumours demonstrate areas of poor response that could benefit from adaptive radiotherapy
Time frame: 7 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
East and North Hertfordshire NHS Trust